EMTN programme: publication
of supplement
9 September 2024: Haleon
plc (the "Company") (LSE/NYSE: HLN) today announces that the
supplement (the "Supplement") to the base listing particulars
(together with the Supplement, the "Base Listing Particulars")
dated 3 May 2024 regarding Haleon UK Capital plc's and Haleon
Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note
Programme, guaranteed by the Company, has been
published.
A copy of the Supplement, together
with the Base Listing Particulars, is available for inspection at
and can be downloaded from:
www.haleon.com/investors/debt-investors
Amanda
Mellor
Company
Secretary
Enquiries
About Haleon
Haleon (LSE / NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please visit
www.haleon.com.
Disclaimer
Please note that the information
contained in the Base Listing Particulars may be addressed to
and/or targeted at persons who are residents of particular
countries (specified in the Base Listing Particulars) only and is
not intended for use and should not be relied upon by any person
outside these countries and/or to whom the offer contained in the
Base Listing Particulars is not addressed. Prior to relying
on the information contained in the Base Listing Particulars, you
must ascertain from the Base Listing Particulars whether or not you
are part of the intended addressees of the information contained in
the Base Listing Particulars.
Your right to access this service is
conditional upon complying with the above requirement.